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When I had completed medical school and graduate school, the scientific 
world did not even have the correct figure for the number of human 
chromosomes. Greggl had recently described the teratogenicity of rubella 
virus infection during pregnancy The teratogenic risk of the folic acid 
antagonists was established2" and there were experimental studies indicating 
that nutritional deficiencies could produce birth defects in anirnal~.~ 
What have we learned and accomplished in the past 50 years? Thousands 
of previously unknow7n genetic diseases have been described and many of 
their genes have been identified since the 1 9 5 0 ~ . ~ ~  The fields of prenatal 
intrauterine diagnoses, intervention and treatment have been created. 
Metabolic and biochemical screening have become standard care for pregnant 
women and newborns. Over 50 teratogenic environmental drugs, chemicals 
and physical agents have been described7-lo using modern epidemiological 
tools and the talents of clinical dysmorpho1ogists."-l7 The basic science and 
clinical rules for evaluating teratogenic risks have been established (Table l ) . I s  
The development of the rubella vaccine and the recognition of the importance 
of adequate folic acid intake in women of reproductive age are forerunners for 
the prevention of birth defects from teratogenic infectious agents and 
nutritional components that are important for normal development. The 
completion of the first stage of the Human Genome Project in the year 2000 
offers the geneticist and teratologist immense opportunities to evaluate the 
concepts of polygenic and multifactorial e t io log ie~ '~ ,~~  of congenital 
malformations. 
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EMOTIONAL IMPACT OF CONGENITAL MALFORMATIONS 
Reproductive problems encompass a multiplicity of diseases including 
sterility, infertility, abortion (miscarriage), stillbirth, congenital malformations 
(due to environmental or hereditary etiologies), fetal growth retardation and 
prernat~rity.7-'"'~ These clinical problems occur commonly in the general 
population and, therefore, environmental causes are not always easy to 
corroborate (Table 2). Severe congenital malformations occur in 3% of births. 
According to the Centers for Disease Control, severe congenital malformations 
(including those birth defects that cause death, hospitalization, and mental 
retardation) necessitate significant or repeated surgical procedures, are 
disfiguring, or interfere with physical performance. That means that each year 
in the US, 120,000 newborns are born with severe birth defects. Genetic 
diseases occur in about 11% of births. Spontaneous mutations account for less 
than 2-3'10 of genetic disease. Therefore, mutations induced from 
preconception exposures of environmental mutagens are difficult end-points 
to document (Table 2). It may surprise the reader to know that birth defects 
Table 2 Background reproductive risks per million pregnancies 
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account for 440,000 children's deaths each year in the low- and middle-income 
nations from congenital malformations. That represents 3.7% of the deaths in 
children. In the high-income countries, congenital malformations are the 
second highest cause of death in children, accounting for 20% of the deaths. 
DISEASES OF AFFLICTION 
Along with cancer, psychiatric illness, and hereditary diseases, reproductive 
Problems have been viewed throughout history as diseases of affliction. 
Inherent in the reactions of most cultures is that these diseases have been 
viewed as punishments for Regardless of the irrationality of this 
viewpoint, these feelings do exist. Ancient Babylonian writings recount tales of 
mothers being put to death because they delivered malformed infants. One 
George Spencer was slain by the Puritans in New Haven in the 17th century, 
the lustorical perspective, and blame others for the occurrence of their congenital 
malformations, infertility, abortions and hereditary diseases. They place the 
responsibility of their illness on environmental agents dispensed by their 
healthcare provider or utilized by their employer."-24 
Reproductive problems alarm the public, the press and some scientists to a 
greater degree than most other diseases. In fact, severely malformed children 
are disquieting to healthcare providers, especially if they are not experienced 
in dealing with these problems. No physician will be comfortable informing a 
family that their child was born without arms and legs. The objective 
evaluation of environmental causes of reproductive diseases is clouded by the 
emotional climate that surrounds these diseases, resulting in the expression of 
partisan positions that either diminish or magnify the environmental risks. 
These non-objective opinions can be expressed by scientists, the laity or the 
press.aZ4 It is the responsibility of every physician to be aware of the 
emotionally charged situation when a family has a child with a birth defect. 
The inadvertent comment by the physician, nurse, resident or student in 
attendance at the time of the child's delivery can have grave consequences for 
the physician and the family. Comments such as, 'Oh, you had an X-ray during 
your pregnancy', or 'You did not tell me that you were prescribed tetracycline 
while you were pregnant', can direct the patient's family to an attorney rather 
than to a teratology or genetic counselor. 
5 
BASIC PRINCIPLES OF TERATOLOGY 
having been convicted of fathering a cyclopean pig, since the P~lritans were unable 
to differentiate between George Spencer's cataract and the malformed pigs cloudy 
In modem times, some individuals with reproductive problems reverse 
Labeling an environmental exposure as teratogenic is inappropriate unless one 
characterizes the exposure with regard to the dose, route of exposure and the 
stage of pregnancy when the exposure occurred. Labeling an agent as 
teratogenic only indicates that it may have the potential for producing 
congenital malformations. A 50-mg dose of thalidomide administered on the 
26th day post-conception has a significant risk of malforming the embryo. That 
same dose taken during the 10th week of gestation will not result in congenital 
 malformation^.^ One milligram of thalidomide taken at any time during 
pregnancy will have no effect on the developing embryo. We know that X- 
irradiation can be t e r a t o g e n i ~ . ~ ~ ~ ~  However, if the dose is too low or the X-ray 
does not directly expose the embryo, there is no increased risk of congenital 
malformations (Fig. l).7,8,26 SO a list of teratogens only indicates teratogenic 
potential. Evaluation of the dose and time of exposure could indicate that there 
is no teratogenic risk or that the risk is significant. 
When evaluating studies dealing with the reproductive effects of any 
environmental agent, important principles should guide the analysis of human 
and animal reproductive studies. Paramount to this evaluation is the 
application of the basic science principles of teratology and developmental 
b i o l ~ g y . ~ , ~ , ~ ~  These principles are as follows: 
I. Exposure to teratogensfollows a toxicological dose-response curve. There is a 
threshold below which no temtogenic efiect will be observed; as the dose ofthe 
teratogen is increased, both the severity andfrequency of reproductive effects will 
increase (Fig. 1; Table 3). 
2. Tke embryonic stage of exposure is critical in determining what deleterious eflects 
zoill be produced and whether any of tlzese effects can be produced hj a known 
teratogen. Some teratogenic Effects have a broad, and others a very narrow, period 
of sensitivity. The most sensitive stage for tlze induction of mental retardation 
from ioiziziizg radiation i s f r o n ~  the 8th to 15tl1 week of pregnancy, a lengthy 
period. Thalidomide's period of sensitivity is about 2 weeks (Table 4).25 
3. Even tlze most potent teratogenic agent cannot produce m e l y  rrmlformatiolz. 
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mutagen 
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Fig. 1. Dose-response relationship of reproductive toxins comparing preconception and 
post-conception risks. Reprouced with permission of Wiley-Liss Inc O 1999 from Brentz6 
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Table 3 Stochastic and threshold dose-response relationships of diseases produced by 
environmental agents 
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4. Most teratogens have a confined grotip of congenital malformations that result I 
after exposure during a critical period of embryonic development. This confined 
grot~p of malformations is referred to as the syndrome that describes the agent's 
teratogenic effects. I 
5. While a grotip of malformations may suggest the possibility of certain teratogens, 
they cannot definitively confirm the causal agen t because some teratogenic 
syndromes mimic genetic syndromes. On  the other hand, the presence of certain 
malformations can eliminate the possibility that a particular teratogenic agent 
was responsible because those malformations have not been demonstrated to be 
part of the syndrome or because the prodliction of that malformation is not 
biologically platisible for that particular alleged tmatogen. I 
The etiology of congenital malformations can be divided into three categories 
- unknown, genetic, and environmental (Table 5). The etiology of a majority of 
human malformations is unknown. A significant proportion of congenital 
malformations of unknown etiology is likely to have an important genetic 
component. In fact, newly published findings are describing genetic causes for 
malformations or syndromes whose etiology were previously listed as 
unknown. Malformations with an increased recurrent risk, such as cleft lip and 
palate, anencephaly, spina bifida, certain congenital heart diseases (pyloric 
stenosis, hypospadias, inguinal hernia, talipes equinovarus, and congenital 
dislocation of the hip) fit in the category of multifactorial disease as well as in 
the category of polygenic inherited disea~e. '~, '~ The multifactorial/threshold 
hypothesis postulates the modulation of a continuum of genetic characteristics 
by intrinsic and extrinsic (environmental) factors. I 
Spontaneous errors of development may account for some of the I 
malformations that occur without apparent abnormalities of the genome or 
Table 5 Etiology of human congenital malformations obsewed during the first year of life* 
nknown 
Polyge 
Multif i 
Spont? 
Synerg 
enetic 
A .  .*--- 
I V I O L C I  I 
phenyl 
deficit 
size an 
Chemic 
hypert 
listic intera 
. - - I  - - A  - 
~d uterine ( 
cals, prescr 
hermia 
ctions of t c  
,:-,...A :. 
smoking a 
, - - , , -  L 
ractions) 
Suspected cause Percentage 
of total 
- 
U 
actorla1 (gene-environment lnte 
aneous errors of development 
G !5 
HULOSOI~I~I drlu S~X-11r1~t.u Irlrierlieu uerleiic disease 
Cytogenetic (chrc 
New mutations 
Environmental 
hn-+--~al conditic,,,,. a t ~ v ~ a v l ~ a a ~ n ,  ulaur:rss, FIIUvLI IIIVrCILIII= 
ketonuria, 
5 
ous agents: ruoella, roxoplasmo 
slmplex, cytomegalovirus, varicella-zoster, Venezuelan equine 
encephalitis, pawovirus B19 3 
Mechanical problems (defor 
constrictions, umbilical cord nru an, fir, umpal t.y 1 8  4 tc 
- 
*Modified from several r e f e r e n ~ e s . ~ . ~ . ' " ~ ~ ~ ~ , ~ '  
:ontents 
iption druc 
lnd nicotin 
- - ,  - - - - -  
js, high-do 
e, starvatic 
sis, syphilis 
. . 
amniotic b 
. A:r.......:h. 
)n, nutritio 
,, herpes 
and ;.. ,+,.;.- 
I radiation, 
environmental influence. Spontaneous errors of development may indicate 
that we may never achieve our goal of eliminating all birth defects because a 
significant percentage of birth defects are due to the statistical probability of 
errors in the developmental process, similar to the concept of spontaneous 
mutation. It is estimated that 3040% of all conceptions are lost before term, 
many within the first 3 weeks of development. The World Health Organization 
estimated that 15% of all clinically recognizable pregnancies end in a 
spontaneous abortion, 50-60% of which are due to chromosomal 
abn~rrnalities.~'-~~ Finally, 3 4 %  of offspring are malformed, which represents 
the background risk for human maldevelopment (Table 2). 
FACTORS AFFECTING SUSCEPTIBILITY TO DEVELOPMENTAL 
TOXICANTS 
A basic tenet of environmentally produced malformations is that teratogens or 
a teratogenic milieu have certain characteristics in common and follow certain 
basic principles. These principles determine the quantitative and qualitative 
aspects of environmentally produced malformations. 
Embryonic stage 
The types and risk of malformations caused by teratogenic agents usually 
results in a spectrum of malformations that varies depending on the stage of 
exposure and the dose. The developmental period at which an exposure occurs 
will determine which structures are most susceptible to the deleterious effects 
of the drug or chemical and to what extent the embryo can repair the damage. 
This period of sensitivity may be narrow or broad, depending on the 
environmental agent and the malformation in question. The period of 
susceptibility to thalidomide-induced limb defects is very narrow (Table 4),25 
while susceptibility period for radiation-induced microcephaly is very broad.26 
Dose or magnitude of the exposure 
The quantitative correlation of the magnitude of the embryopathic effects to 
the dose of a drug, chemical or other agent is referred to as the dose-response 
relationship. This is extremely important when comparing effects among 
different species because the use of mg/kg doses is ,at most, a rough 
approximation. Dose equivalence among species for drugs and chemicals can 
only be accomplished by performing pharmacokinetic studies, metabolic 
studies and dose-response investigations in the human and the species being 
studied, while ionizing radiation exposures in rads or Sieverts (Sv) are 
comparable in most mammalian species.26 
Threshold dose 
The threshold dose (no-adverse-effect-level, NOAEL) is the dosage below 
which the incidence of death, malformation, growth retardation, or functional 
deficit is not statistically greater than that of controls (Fig. 1; Table 3). The 
threshold level of exposure is usually from less than one to two orders of 
magnitude below the teratogenic or embryopathic dose for drugs and 
chemicals that kill or malform half the embryos. An exogenous teratogenic 
agent, therefore, has a no-effect dose as compared to mutagens or carcinogens 
that have a stochastic dose response curve (Fig. 1; Table 3). Stochastic 
phenomena, namely mutation and oncogenesis, are hypothesized not to have 
a threshold. Therefore, there is no exposure that does not have a theoretical 
risk. The severity and incidence of malformations produced by every 
exogenous teratogenic agent that has been appropriately studied have 
exhibited threshold phenomena during organogenesis. 
Pharmacokinetics and metabolism of the drug or chemical 
The physiological alterations in pregnancy and the bioconversion of 
compounds can significantly influence the teratogenic effects of drugs and 
chemicals by affecting absorption, body distribution, active form(s) and 
excretion of the compound. 
Physiological alterations in the mother during pregnancy afect the plzarmacokinetics 
of drugs: 
1. Decreased gastrointestinal motility and increased intestinal transit time 
resulting in delayed absorption of drugs absorbed in the small intestine 
due to increased stomach retention and enhanced absorption of slowly 
absorbed drugs. 
2. Decreased plasma albumin concentration which alters the kinetics of 
compound normally bound to albumin. 
3. Increased plasma and extracellular fluid volumes that affect concentration- 
dependent transfer of compounds. 
4. Renal elimination, which is generally increased but is influenced by body 
position during late pregnancy. 
5. Inhibition of metabolic inactivation in the maternal liver. 
6. Variations in uterine blood flow, although little is known about how this 
affects transfer across the placenta. 
Thefetus also undergoes physiological alterations that aflect the phnrmacokinefics of drugs: 
1. The amount and distribution of fat varies with development and affects 
the distribution of lipid-soluble drugs and chemicals. 
2. The fetal circulation contains a higher concentration of unbound drug largely 
because the plasma fetal protein concentrations are lower than in the adult. 
3. The functional development of pharmacological receptors is likely to 
proceed at different rates in the various tissues. 
4. Drugs excreted by the fetal kidneys may be recycled via amniotic fluid 
swallowing by the fetus. 
The role the placenta plays in drug pharmacokinetics has been reviewed by 
Juchau and Rettie35 and involves: (i) transport; (ii) the presence of receptors sites 
for a number of endogenous and xenobiotic compo~mds (P-adrenergic, 
glucocorticoid, epidermal growth factor, IgG-Fc, insulin, low-density lipoproteins, 
opiates, somatomedin, testosterone, transcobalamin II, transferrin, folate, 
retinoid); and (iii) the bioconversion of xenobiotics. Bioconversion of xenobiotics 
has been shown to be important in the teratogenic activity of several xenobiotics. 
There is strong evidence that reactive metabolites of cyclophosphamide, 2- 
acety:aminofluorene, and nitroheterocycles (niridazole) are the proximal 
teratogens. There is also experimental evidence that suggests that other chemicals 
undergo conversion to intermediates that have deleterious effects on embryonic 
development including phenytoin, procarbazine, rifampicin, diethylstilbestrol, 
some benzhydrylpiperazine ,antihistamines, adriamycin, testosterone, 
ben~o(a)~~rene ,  methoxyethanol, caffeine, and paraquat. 
The major site of bioconversion of chemicals in vivo is likely to be the 
maternal liver. Placental cytochrome P450-dependent monooxygenation of 
xenobiotics will occur at low rates unless induced by such compounds as those 
found in tobacco smoke. However, the rodent embryo and yolk sac have been 
shown to possess functional cytochrome P450 oxidative isozyrnes capable of 
converting pro-teratogens to active metabolites during early organogenesis. In 
addition, cytochrome P450-independent bioactivation has been suggested: for 
example, there is strong evidence that the rat embryo can reductively convert 
niridazole to an embryotoxic metabolite. 
As defined by Juchau and Rettie,35 there are several experimental criteria 
that would suggest that a suspected metabolite is responsible for the in vivo 
teratogenic effects of a chemical or drug: (i) the chemical must be convertible 
to the intermediate; (ii) the intermediate must be found in or have access to the 
tissue(s) affected; (iii) the embryotoxic effect should increase with the 
concentration of the metabolite; (iv) inhibiting the conversion should reduce 
the embryotoxic effect of the agent; (v) promoting the conversion should 
increase the embryotoxicity of the agent; (vi) inhibiting or promoting the 
conversion should not alter the target tissues; and (vii) inhibition of 
biochemical inactivation should increase the embryotoxicity of the agent. It is 
readily apparent why there may exist marked qualitative and quantitative 
differences in the species' response to a teratogenic agent. 
Placental transport 
The placenta controls the exchange between the embryo and the maternal 
organism. The placenta varies in structure and function among species and for 
each stage of gestation. Thus, differences in placental function and structure 
may affect our ability to apply teratogenic data developed in one species 
directly to other species, including the human. Yet, as pharmacokinetic 
techniques and the actual measurement of metabolic products in the embryo 
become more sophisticated, the appropriateness of utilizing animal data to 
project human effects may impr0ve.3~ 
While it has been alleged that the placental barrier was protective and, 
therefore, harmful substances did not reach the embryo, it is now clear that 
there is no 'placental barrier,' per se. Yet the package inserts on many drugs 
state that: 'this drug crosses the placental barrier'.2h The uninitiated may infer 
From this statement that this characteristic of a drug is both unusual and 
hazardous. The fact is that most drugs and chemicals cross the placenta. It will 
be a rare chemical that will cross the placental barrier in one species and be 
unable to reach the fetus in another. No such chemical exists except for selected 
proteins whose actions are species-specific. 
Genetic differences 
The genetic constitution of an organism is an important factor in the 
susceptibility of a species to a drug or chemical. More than 30 disorders of 
increased sensitivity to drug toxicity or effects in the human are due to an 
Inherited trait. 
ENVIRONMENTAL AGENT EXPOSURE DURING PREGNANCY 
RESULTING IN REPRODUCTIVE TOXICITY7-9 
Table 6 lists environmental agents that have resulted in reproductive toxicity 
and or congenital malformations in human populations. The list cannot be 
used in isolation because so many other parameters must be considered in 
analyzing the risks in individual patients. Many of these agents represent a 
very small risk while others may represent substantial risk. The risks will vary 
with the magnitude, timing and length of exposure. More information can be 
obtained from more extensive reviews or summary articles. Table 7 includes 
agents that have had concerns raised about their reproductive risks but, after 
Table 6 Proven human teratogens or embryotoxins: drugs, chemicals, milieu and 
physical agents that have resulted in human congenital malformations 
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agents used t o  treat cancer have a theoretical risk for producing 
nalformations in the fetus when administered to  pregnant women. 
!specially since most of these drugs are teratogenic in animals, but 
he clinical data are not consistent. Many of these drugs have not 
)een shown to  be teratogenic, but the numbers of cases in the 
>tudies are small. Caution is  the byword 
Diethylstilbestrol - administration during pregnancy produces genital 
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nffects, such as adenosis can be quite high 
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Insulin shock therapy - this therapeutic modality when administered to pregnant 
women resulted in microcephaly, mental retardation. This therapy is no 
longer used 
Lithium therapy - continuous exposure during pregnancy for the treatment of 
manic-depressive illness has an increased risk for Ebstein's anomaly 
and other malformations, but the risks appear t o  be very low 
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I Table 6 (continued) Proven human teratogens or embryotoxins: drugs, chemicals, 
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careful and complete evaluation, the agents were found not to represent an 
increased reproductive risk.-' 
References for the environmental agents can be found in review articles and 
texts dealing with teratogenesi~.~,~,~~,~~,~~,~~~~ 
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ROLE OF THE PHYSICIAN IN COUNSELING FAMILIES 
The clinician must be cognizant of the fact that many patients believe that most 
congenital malformations are caused by a drug or medication taken during 
pregnancy. Counseling patients about reproductive risks requires a significant 
degree of both knowledge and skill. Physicians must also realize that 
erroneous counseling by inexperienced health professionals may be a stimulus 
to non-meritorious l i t i ga t i~n .~~  
Unfortunately, some individuals have assumed that if a drug or chemical 
causes birth defects in an animal model or in vitro system at a high dose, then 
it has the potential for producing birth defects at any dose.48,49 This may be 
reinforced by the fact that many teratology studies reported in the literature 
using several doses do not determine the no-effect dose. 
Ignoring the basic tenets of teratology appears to occur most commonly in the 
evaluation of environmental toxic exposures where the exposure was very low or 
unknown and the agent has been reported to be teratogenic at a very high dose or 
a maternally toxic dose in animal models.48," 9 most instances, but of course not 
all instances, the actual population exposure is revealed to be orders of magnitude 
below the threshold dose and the doses that were used in animal studies or toxic 
exposures in the population. This has occurred with 2,4,5-T, PCBs, Pb, Cd, 
pesticides, herbicides, veterinary hormones and some industrial exposures. 
Unfortunately, we do have examples where environmental disasters have 
been responsible for birth defects or pregnancy loss in exposed populations 
(methyl mercury in Japan, PCBs in the Orient, organic mercury in the Middle 
East, lead poisoning in the 19th and early 20th centuries) and we do have many 
examples of the introduction of teratogenic drugs (Table 6). Therefore, we can 
never generalize as to whether a chemical or drug is safe or hazardous unless 
we know the magnitude of the exposure. 
Before their baby is born, parents may be concerned about the risks of 
various environmental exposures. If the child is born with congenital 
malformations they may question whether there was a causal relationship 
with an environmental exposure: 
1. Has the environmental agent been proven to increase the risk of congenital 
malformations in exposed human poptllatim? In other mds, is the agent a proven 
human teratogen? 
2. Should a zvomun of reproductive age or who is pregnant be concerned about increased 
risks of reproductive efects from exposure to a particular environmental agent? 
3. Ifa child is born zuith congenital malformations and the mother was exposed during her 
pregnancy to a particular environmental agent, was the agent responsible@ the child's 
birth defcfs? 
4. Should a physicinn report or publish a case ofa patient or cluster ofpatients who were 
born with congenital rnalfmmations and whose mother was exposed to an 
environmental agent?50 
Scholarly evaluation 
When a physician responds to a parent's inquiry ('What caused my child's 
birth defect?'), the physician should respond in the same scholarly manner that 
would be utilized in performing a differential diagnosis for any clinical 
problem. Physicians have a protocol for evaluating complex clinical problems; 
i.e. 'fever of unknown origin', 'failure to thrive', 'congestive heart failure', or 
'respiratory distress'. If a mother of a malformed lnfant had some type of 
exposure during pregnancy, such as a diagnostic radiological examination or 
medication during pregnancy, the consulting physician should not support or 
suggest the possibility of a causal relationship before performing a complete 
evaluation. Likewise, if a pregnant woman who had not yet delivered had 
some type of exposure during pregnancy, the consulting physician should not 
support or suggest the possibility that the fetus is at increased risk before 
performing a complete evaluation. As mentioned previously, only a small 
percentage of birth defects are due to prescribed drugs, chemicals and physical 
agents (Table 5).'.36fi Even when the drug is listed as a teratogen, it has to have 
been administered during the sensitive period of development for that drug 
and above the threshold dose for producing teratogenesis. Furthermore, the 
malformations in the child should be the malformations that are included in 
the teratogenic syndrome produced by that drug. It should be emphasized that 
a recent analysis pointed out that there are no drugs with measurable 
teratogenic potential in the list of the 200 most prescribed drugs in the US5' 
After a complete examination of the child and a review of the genetic and 
teratology medical literature, the clinician must decide on whether the child's 
malformations are due to a genetic cause or an environmental toxin or agent. 
The clinician may not be able to conclude, definitively or presumptively, the 
etiology of the child's birth defects. This information must then be conveyed to 
the patient in an objective and compassionate manner. A similar situation 
exists if a pregnant women has been exposed to a drug, chemical or physical 
agent, since the mother will want to know the risk of that exposure to her 
unborn child. If one wishes to answer the generic question, 'Is a particular 
environmental drug, chemical or physical agent a reproductive toxicant?' then 
a formal approach is recommended that includes a 5-part evaluation as 
described in Table l . I s  
-,me typical analyses of the risks of reproductive effects for Bendectin, sex 
diagnostic ultrasound, and electromagnetic fields demonstrate the 
of an organized approach to determine whether an environmental 
agent has been demonstrated to be a reproductive t o ~ i n . ~ '  
There are resources that can assist the physician with the medical literature 
and the clinical evaluation of the patient.5,6,",1"*4247 
Clinical evaluation 
There are many articles and books that can assist the physician with the clinical 
evaluation, although physician training programs do not usually prepare 
generalists to perform sophisticated genetic counseling or teratology 
counseling."J6 Besides the usual history and physical evaluation, the physician 
has to obtain information about the nature, magnitude and timing of the 
exposure. The physical examination should include descriptive and 
quantitative information about the physical characteristics of the child. While 
some growth measurements are routine, many measurements utilized by these 
specialized counselors are not part of the usual physical examination, i.e. 
palpebral fissure size, ear length, intercanthal distances, total height-to-trunk 
ratio, and many others. Important physical variations in facial, hand and foot 
structure as well as other anatomical structures may be suggestive of known 
syndromes, either teratoiogic or genetic. 
Evaluation of the reproductive risk of an environmental exposure that 
occurred during pregnancy or the cause of a child's malformation in 
which an exposure occurred during pregnancy 
The vast majority of consultations involving pregnancy exposures conclude 
that the exposure does not change the reproductive risks in that pregnancy. In 
many instances, the information that is available is so vague that the counselor 
cannot reach a definitive conclusion about the magnitude of the risk. 
Information that is necessary for this evaluation is: 
1. What was the nature of the exposure? 
2. Is the exposure agent identifiable? If the agent is identifiable, has it been 
definitively identified as a reproductive toxin with a recognized 
constellation of malformations or other reproductive effects? 
3. When did the exposure occur during embryonic and fetal development? 
4. If the agent is known to produce reproductive toxic effects, was the 
exposure above or below the threshold for these effects? 
5. Were there other significant environmental exposures or medical problems 
during the pregnancy? 
6. Is this is a wanted pregnancy or is the family ambivalent about carrying 
this baby to term? 
7. What is the medical and reproductive history of this mother with regard 
to prior pregnancies and the reproductive history of the family lineage? 
Evaluation of the reproductive risk of an environmental exposure that 
occurred during pregnancy 
After obtaining all this information, the counselor is in a position to provide 
the family with an estimate of the reproductive risks of the exposure. Here are 
some examples of consultations that have been referred to our clinical 
teratology service: 
Patient 7 
A 26-year-old pregnant woman was in an automobile accident in her 10th 
week of pregnancy and sustained a severe concussion. Although she did not 
convulse post-injury, the treating neurosurgeon prescribed 300 mg of 
diphenylhydantoin during her first 24 hours in the hospital. Fortunately, she 
recovered from the injury without any sequelae but her primary physician was 
concerned that she had received an anticonvulsant associated with a 
teratogenic syndrome. No other exposure to reproductive toxins occurred in 
this pregnancy and the family history for congenital malformations was 
negative, except for an uncle with neurofibromatosis. The primary physician 
requested a consultation with regard to the teratogenic risk. While 
diphenylhydantoin administered chronically throughout pregnancy has been 
associated with a low incidence of characteristic facial dysmorphogenesis, 
reduced mentation, clef palate and digital hypoplasia, there are no data to 
indicate that one day of therapy would cause any of the features of this 
syndrome. Furthermore, the lip and palate have completed their development 
by the 10th week. This was a wanted pregnancy and the mother chose to 
continue her pregnancy. She delivered a normal 3370-g boy at term. 
Patient 2 
A 25-year-old woman was seen in the emergency service of her local hospital 
with nausea, vomiting and diarrhea. She had just returned from a cruise on 
which a number of the passengers became ill on the last day of the trip with 
similar symptoms. The emergency ward physician ordered a pregnancy test 
followed by a flat plate of the abdomen because there was evidence of 
peritoneal irritation. Both of these studies were negative. But 1 week later, she 
missed her menstrual period and a week later her pregnancy test was positive. 
Her obstetrician was concerned because she had been exposed to a 
radiological procedure at a time when she was pregnant. The obstetrician 
referred the patient for counseling after obtaining an ultrasound that indicated 
that the embryo was approximately 7 days post-conception at the time of the 
radiological examination. The patient advised the counselor that she was 
ambivalent about the pregnancy because of the 'dangers' of the X-rays to her 
embryo. The estimated exposure to the embryo was less than 500 mrad (0.005 
Sv). This exposure is far below the exposure that is known to affect the 
developing embryo. Just as important is the fact that the embryo was exposed 
during the first 2 weeks post-conception, a time that is less likely to increase 
the risk of teratogenesis, even if the exposure was much higher.26*52 After 
evaluation of the family history and after she received counseling about the 
risks of the X-ray, the prospective mother decided to continue the pregnancy. 
She delivered a 3150-g normal baby. 
 tio on of whether a child born with congenital malformations was 
caused by an environmental exposure during pregnancy, has a genetic 
etiology or whose cause cannot be determined 
Patient 3 
A mother of a 30-year-old man born in the Azores in 1960 with congenital 
absence of the right leg below the knee had pursued compensation for her son 
because she was certain that she must have received thalidomide during her 
pregnancy.24 The German manufacturer of thalidomide refused compensation 
claiming that thalidomide had never been distributed in the Azores. The 
mother fervently believed that thalidomide was responsible for her son's 
malformations and I received a letter from her asking for my opinion. I 
requested her son's medical records, X-rays and photographs of the 
malformations. She sent me the X-ray studies of his hips and legs and his 
complete evaluation performed at the local hospital in the Azores. He had 
none of the other stigmata of thalidomide embryopathy (pre-axial limb 
defects, phocomelia, facial hemangioma, ear malformations, deafness, 
crocodile tears, ventricular septa1 defect, intestinal or gall bladder atresia, 
kidney malformations). Most importantly, his limb malformations were not of 
the thalidomide type. He had a unilateral congenital amputation, with no 
digital remnants at the end of the limb. His pelvic girdle was completely 
normal which would be unusual in a thalidomide malformed limb. Finally, his 
limb defect involved only one leg; the other leg was completely normal. This 
would be very unusual in a true thalidomide embryopathy. In this particular 
case, the young man had a congenital amputation, probably due to vascular 
disruption, etiology unknown. Known causes of vascular disruptive 
malformations are cocaine, misoprostol and chorionic villous sampling. It is 
difficult to determine whether any amount of appropriate counseling will put 
closure on this problem for this mother. 
Patient 4 
A family claimed that the anti-nausea medication, B e n d e ~ t i n , 3 ~ ~ ~ , ~ ~  taken by the 
mother of a malformed boy, was responsible for her son's congenital limb 
reduction defects. Bendectin was t,&en during the mother's pregnancy after 
the period of limb organogenesis, but some limb malformations can be 
produced by teratogens later in pregnancy. The malformation was 
unaccompanied by any other dysmorphogenetic effects. The boy's 
malformations were the classical split-hand, split-foot syndrome, which is 
dominantly inherited. This malformation'has a significant portion of cases that 
are due to a new mutation. Since neither parent manifested the malformation, 
the conclusion had to be that a new mutation had occurred in the sex cells of 
one of the parents. Therefore, the risk of this malformation occurring in the 
offspring of this boy would be 50%. Obviously, Bendectin was not responsible 
for this child's malformations. In spite of the obvious genetic etiology of the 
malformed child's birth defects, a legal suit was filed. A jury decided for the 
defendant - namely, that Bendectin was not responsible for the child's birth 
defects. 
It should be apparent that determining the reproductive risks of an exposure 
during pregnancy or the etiology of a child's congenital malformations is not a 
simple process. It involves a careful analysis of the medical and scientific 
literature pertaining to the reproductive toxic effects of exogenous agents in 
humans and animals, as well as an evaluation of the exposure and biological 
plausibility of an increased risk or a causal connection between the exposure 
and a child's congenital malformation. It also involves a careful physical 
examination, a review of the scientific literature pertaining to genetic and 
environmental causes of the malformations in question. Abridged counseling 
based on superficial and incomplete analyses is a dis-service to the family. 
CONCLUSIONS 
There have been significant advances in embryology, teratology, reproductive 
biology, genetics and epidemiology in the last years that have provided 
scientists and clinicians with a better perspective on the causes of congenital 
malformations. We still cannot provide the families of children with 
malformations a definitive diagnosis and etiology lor every malformed child. 
However, there are numerous environmental drugs, chemicals and physical 
agents that have been documented to produce congenital malformations and 
reproductive effects. While this multitude of teratogenic agents (agents that 
produce congenital malformations from exposures during pregnancy) account 
for only a small proportion of malformations, it is important to remember that 
all these environmentally produced birth defects are potentially preventable. 
The most common known cause of congenital malformations is genetic, but 
the largest group, unfortunately, is unknown. There are a number of important 
clinical rules that are important for clinicians to utilize when determining the 
cause of their patient's congenital malformations. 
1. No teratogenic agent should be described qualitatively as a teratogen (an agent 
that causes birth defects), since a teratogenic exposure includes not only the 
agent, but also the dose and the time in pregnancy when the exposure occurs. 
2. Even agents that have been demonstrated to result in malformations 
cannot produce every type of malformation. Known teratogens may be 
presumptively implicated by the spectrum of malformations they produce 
(the syndrome that describes the clinical manifestations of the teratogenic 
agent). It is easier to exclude an agent as a cause of birth defects than to 
definitively conclude that it was responsible for birth defects, because of 
the existence of genocopies of some teratogenic syndromes. 
3. When evaluating the risk of exposures, the dose is a crucial component in 
determining the risk. Teratogenic agents follow a toxicological 
dose-response curve. This means that each teratogen has a threshold dose, 
below which, there is no risk of teratogenesis, no matter when in 
pregnancy the exposure occurred. 
4. The evaluation of a child with congenital malformations cannot be 
adequately performed unless it is approached with the same scholarship 
and intensity as the evaluation of any other complicated medical problem. 
5. Each physician must recognize the consequences of providing erroneous 
reproductive risks to pregnant women exposed to drugs and chemicals 
during pregnancy or alleging that a child's malformations are due to an 
environmental agent without performing a complete and scholarly 
evaluation. 
6. Unfortunately, clinical teratology and clinical genetics are not emphasized 
in medical school and residency education programs. But physicians have 
a multitude of educational aids to assist them in their evaluations, which 
include consultations with clinical teratologists and geneticists, the 
medical literature and the OMIM website. 
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